Research Paper Volume 12, Issue 5 pp 4573—4591
APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma
Figure 6. APEX1 is a better diagnostic biomarker than AFP in early stage HCC patients. (A) The diagnostic values of APEX1 and AFP in stage 1 HCC patients based on ROC curve analysis is shown. (B) The best cut-off values for APEX1 and AFP were calculated using the Youden index in combination with the Product index. (C) The analysis of Pearson correlation co-efficients for APEX1 and AFP expression in the HCC and adjacent normal liver tissues is shown. (D) The graphical representation shows the mean diagnostic sensitivity of APEX1 and AFP in HCC patients from the GSE25097 and GSE63898 datasets. APEX1 shows significantly higher diagnostic value compared to AFP.